Genistein

Generic Name: Genistein

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₀O_₅

CAS Number: 446-72-0

Unique Ingredient Identifier: DH2M523P0H

Background: An isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA topoisomerases, type II) activity and is used as an antineoplastic and antitumor agent. Experimentally, it has been shown to induce G2 phase arrest in human and murine cell lines.

Additionally, genistein has antihelmintic activity. It has been determined to be the active ingredient in Felmingia vestita, which is a plant traditionally used against worms. It has shown to be effective in the treatment of common liver fluke, pork trematode and poultry cestode.

Further, genistein is a phytoestrogen which has selective estrogen receptor modulator properties. It has been investigated in clinical trials as an alternative to classical hormone therapy to help prevent cardiovascular disease in postmenopausal women .

Natural sources of genistein include tofu, fava beans, soybeans, kudzu, and lupin.

Indication: Currently Genistein is being studied in clinical trials as a treatment for prostate cancer.

Associated Conditions: Calcium Deficiency, Deficiency, Vitamin D, Osteodystrophy, Osteomalacia, Osteoporosis

Clinical Trials

Genistein in Preventing Breast Cancer in Women at High Risk for Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: genistein
Drug: placebo
Other: laboratory biomarker analysis

First Posted Date: 2006-02-13

Last Posted Date: 2017-02-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 126

Registration Number: NCT00290758

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Isoflavones and the Coronary Circulation in Men and Women With Coronary Artery Disease

Phase 2

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Placebo
Drug: Genistein

First Posted Date: 2006-02-07

Last Posted Date: 2019-08-05

Lead Sponsor: Imperial College London

Target Recruit Count: 71

Registration Number: NCT00287690

Locations: 🇬🇧
Royal Brompton & Harefield NHS Trust, London, United Kingdom

Effects of GCP on Prostate Cancer.

Not Applicable

Completed

Conditions: Prostate Cancer

First Posted Date: 2005-12-23

Last Posted Date: 2010-06-29

Lead Sponsor: University of California, Davis

Target Recruit Count: 62

Registration Number: NCT00269555

Locations: 🇺🇸
University of California, Davis, Sacramento, California, United States

Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer

Phase 2

Completed

Conditions: Stage II Bladder Cancer AJCC v6 and v7
Recurrent Bladder Carcinoma
Stage III Bladder Cancer AJCC v6 and v7
Stage I Bladder Cancer AJCC v6 and v7

Interventions: Other: Laboratory Biomarker Analysis
Drug: Genistein
Other: Placebo Administration
Other: Pharmacological Study
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2005-07-11

Last Posted Date: 2021-06-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00118040

Locations: 🇺🇸
University of Wisconsin Chemoprevention Consortium, Madison, Wisconsin, United States
🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸
Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States

and more 7 locations